EXAS

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Wall Street analysts forecast EXAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Exact Sciences Corp revenue for the last quarter amounts to 850.74M USD, increased 20.05 % YoY.

Exact Sciences Corp. EPS for the last quarter amounts to -0.10 USD, decreased -52.38 % YoY.

Exact Sciences Corp (EXAS) has 6900 emplpoyees as of January 10 2026.

Today EXAS has the market capitalization of 19.38B USD.